Tevogen Bio (NASDAQ:TVGN) Announces Quarterly Earnings Results, Beats Expectations By $0.80 EPS

Tevogen Bio (NASDAQ:TVGN – Get Free Report) released its quarterly earnings data on Monday. The company reported ($1.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.56) by $0.80, FiscalAI reports.

Tevogen Bio Stock Down 6.4%

TVGN stock traded down $0.40 during trading on Tuesday, reaching $5.82. The company’s stock had a trading volume of 399 shares, compared to its average volume of 20,245. Tevogen Bio has a 1 year low of $3.64 and a 1 year high of $24.91. The company’s fifty day moving average is $6.72 and its 200-day moving average is $7.68. The company has a market capitalization of $37.89 million, a P/E ratio of -1.26 and a beta of 0.21.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tevogen Bio in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Tevogen Bio has an average rating of “Reduce” and an average target price of $100.00.

Check Out Our Latest Analysis on Tevogen Bio

Tevogen Bio Company Profile

(Get Free Report)

Tevogen Bio is a clinical-stage biotechnology company developing cell-based immunotherapies. Its ExacTcell platform uses donor-derived, antigen-specific T cells designed to recognize and attack disease-associated targets, with the goal of making therapies available without creating a custom treatment for each patient. The company’s lead investigational candidate, TVGN 489, is a T-cell therapy being developed for COVID-19. Tevogen is also pursuing potential applications of its platform in cancer and other diseases.

Further Reading

Earnings History for Tevogen Bio (NASDAQ:TVGN)

Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.